A prospective natural-history study of coronary atherosclerosis.
Gregg W Stone, Akiko Maehara, Alexandra J Lansky...
https://pubmed.ncbi.nlm.nih.gov/21247313/Actively Recruiting
Led by China National Center for Cardiovascular Diseases · Updated on 2026-09-24
5000
Participants Needed
1
Research Sites
260 weeks
Total Duration
Researchers are evaluating two different strategies for percutaneous coronary intervention PCI in patients with ST-segment elevation myocardial infarction STEMI who have disease in multiple coronary vessels. This study compares the Functional and Angiography-derived Strain inTegration FAST technique, which uses next-generation quantitative flow ratio QFR and radial wall strain RWS measurements, to a standard treatment strategy. The main goal is to see which approach leads to better long-term clinical outcomes, focusing on major adverse cardiac events including death, myocardial infarction, or ischemia-driven revascularization. Participants are randomly assigned to one of two groups. In the FAST guided group, QFR is measured in non-infarct arteries with specific lesion severity criteria, and PCI is performed based on QFR and RWS thresholds or lesion severity. Post-PCI QFR measurements guide further procedures if needed. In the standard treatment group, PCI is done on lesions with visual diameter stenosis 70% or more, and fractional flow reserve FFR or instantaneous wave-free ratio iFR guide treatment decisions for lesions with 50-70% stenosis. Patients are followed for several years with scheduled clinic visits or phone calls. During the study, participants will have follow-up visits or phone contacts at 1 month, 6 months, and annually up to 5 years. Researchers will monitor for major adverse cardiac events, cardiovascular death, and myocardial infarction, among other outcomes such as procedural success and quality of life. Safety and health status will be assessed regularly to understand the long-term impact of the two PCI strategies in this high-risk patient group.
CONDITIONS
The FAVOR V AMI Trial
B
Bo Xu, MBBS
L
Lei Song, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
China National Center for Cardiovascular Diseases
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to the time needed to complete PCI procedures
Participants undergo PCI guided either by the FAST technique or standard treatment strategy based on random assignment.
Duration - Approximately 5 years
Participants have follow-up visits or phone calls at 1 month, 6 months, and annually up to 5 years to monitor heart health and study outcomes.
Scheduled visits or calls at 1 month, 6 months, and yearly
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gregg W Stone, Akiko Maehara, Alexandra J Lansky...
https://pubmed.ncbi.nlm.nih.gov/21247313/Tim Heller, Peter Ong, Udo Sechtem...
https://pubmed.ncbi.nlm.nih.gov/42423587/David Erlinge, Akiko Maehara, Ori Ben-Yehuda...
https://pubmed.ncbi.nlm.nih.gov/33714389/Shamir R Mehta, David A Wood, Robert F Storey...
https://pubmed.ncbi.nlm.nih.gov/31475795/Bo Xu, Shengxian Tu, Lei Song...
https://pubmed.ncbi.nlm.nih.gov/34742368/Etienne Puymirat, Guillaume Cayla, Tabassome Simon...
https://pubmed.ncbi.nlm.nih.gov/33999545/Shengxian Tu, Daixin Ding, Yunxiao Chang...
https://pubmed.ncbi.nlm.nih.gov/33660921/Huihong Hong, Chunming Li, Juan Luis Gutiérrez-Chico...
https://pubmed.ncbi.nlm.nih.gov/36073027/China National Center for Cardiovascular Diseases
Lead Sponsor